nach oben

The European Journal of Health Economics

Erschienen in:

01.09.2015 | Editorial

Western European markets for biosimilar and generic drugs: worth differentiating

verfasst von: Livio Garattini, Alessandro Curto, Katelijne van de Vooren

Erschienen in: The European Journal of Health Economics | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Excerpt

Health is a typical field where the economic theory of market competition does not enjoy the basic conditions to work. The pharmaceutical market, in which the most important private health care industry flourishes, is no exception; rather, it is one of the most striking examples of market failure (on both the demand and supply sides) caused by lack of price competition. To tackle these problems, public intervention on pricing and reimbursement has traditionally been far more extensive than on most other goods. …

EMA. European Public Assessment Reports. Biosimilars. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 15 Jan 2015

McCarthy, J.E.: Basic marketing. A managerial approach. Irwin RD, Homewood (1964)

EMA/393905/2006 Rev 2. Questions and answers on generic medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500012382.pdf (2012). Accessed 9 Dec 2014

EMA. CPMP/EWP/QWP/1401/98 Rev. 1/Corr **. Guideline on the investigation of bioequivalence. London. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (2010). Accessed 9 Dec 2014

EMA/837805/2011. Questions and answers on biosimilar medicines (similar biological medicinal products). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf (2012). Accessed 9 Dec 2014

Dörner, T., Strand, V., Castañeda-Hernández, G., et al.: The role of biosimilars in the treatment of rheumatic diseases. Ann. Rheum. Dis. 72(3), 322–328 (2013)CrossRefPubMed

Weise, M., Kurki, P., Wolff-Holz, E., Bielsky, M.C., Schneider, C.K.: Biosimilars: the science of extrapolation. Blood 124(22), 3191–3196 (2014)CrossRefPubMed

van der Zee, J., Kroneman, M.W.: Bismarck or Beveridge: a beauty contest between dinosaurs. BMC Health Serv Res 7, 94 (2007)PubMedCentralCrossRefPubMed

Schäfer, W., Kroneman, M., Boerma, W., et al.: The Netherlands: health system review. Health Syst. Transit. 12(1), v–xxvii, 1–228 (2010)

10.

Hassali, M.A., Wong, Z.Y., Alrasheedy, A.A., Saleem, F., Mohamad Yahaya, A.H., Aljadhey, H.: Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. Health Policy 117(3), 297–310 (2014)CrossRefPubMed

11.

Garattini, L., Tediosi, F.: A comparative analysis of generics markets in five European countries. Health Policy 51(3), 149–162 (2000)CrossRefPubMed

12.

Miguel, L.S., Augustin, U., Busse, R., et al.: Recognition of pharmaceutical prescriptions across the European Union: a comparison of five Member States’ policies and practices. Health Policy 116(2–3), 206–213 (2014)CrossRefPubMed

13.

Taylor L. France moving ahead with biosimilar substitution. http://www.pharmatimes.com/Article/14-04-13/France_moving_ahead_with_biosimilar_substitution.aspx (2014). Accessed 9 Dec 2014

14.

GKV-Spitzenverband. Rahmenvorgaben nach § 84 Abs. 7 SGB V—Arzneimittel—für das Jahr 2015 vom 26 September 2014. http://www.gkv-spitzenverband.de/suche/suche?default=true&query=biosimilar&x=0&y=0. Accessed 9 Dec 2014

15.

Weise, M., Bielsky, M.C., De Smet, K., et al.: Biosimilars: what clinicians should know. Blood 120(26), 5111–5117 (2012)CrossRefPubMed

16.

Farfan-Portet, M.I., Gerkens, S., Lepage-Nefkens, I., et al.: Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ 15, 223–228 (2014)PubMedCentralCrossRefPubMed

17.

Godman, B., Shrank, W., Wettermark, B., et al.: Use of generics—a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3(8), 2470–2494 (2010)PubMedCentralCrossRef

18.

Dylst, P., Vulto, A., Simoens, S.: Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy 101(2), 146–152 (2011)CrossRefPubMed

19.

European Commission. Pharmaceuticals: sector inquiry and follow up. Final report, factsheet 1: prices, time to generic entry and consumer savings. http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html (2009). Accessed 9 Dec 2014

20.

Woerkom, M.V., Piepenbrink, H., Godman, B., et al.: Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in the Netherlands: influence and future implications. J. Comp. Eff. Res. 1(6), 527–538 (2012)CrossRefPubMed

21.

Giuliani, G., Selke, G., Garattini, L.: The German experience in reference pricing. Health Policy 44(1), 73–85 (1998)CrossRefPubMed

22.

Bennett, C.L., Chen, B., Hermanson, T., et al.: Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 15(13), e594–e605 (2014)PubMedCentralCrossRefPubMed

23.

Blackstone, E.A., Joseph, P.F.: The economics of biosimilars. Am Health Drug Benefits 6(8), 469–478 (2013)PubMedCentralPubMed

24.

Curto, A., van de Vooren, K., Lo Muto, R., Duranti, S., Garattini, L.: Regional tenders on biosimilars in Italy, potentially competitive? GaBI J 2(3), 123–129 (2013)CrossRef

25.

Sahuquillo MR. El Gobierno lanza la primera compra centralizada de fármacos. El Pais 27 December 2011. http://sociedad.elpais.com/sociedad/2012/12/27/actualidad/1356641122_491730.html. Accessed 9 Dec 2014

26.

Ortega E. Medicamentos biológicos de marca y biosimilares competirán en los mismos concursos públicos. Redacción Médica 25 November 2014. http://www.redaccionmedica.com/secciones/industria/biologicos-de-marca-y-biosimilares-competiran-en-los-mismos-concursos-publicos-5934. Accessed 9 Dec 2014

27.

GaBI Journal. US$67 billion worth of biosimilar patents expiring before 2020. http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020 (2014). Accessed 9 Dec 2014

28.

EMA CHMP/437/04. Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf (2005). Accessed 9 Dec 2014

29.

van de Vooren, K., Curto, A., Garattini, L.: Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU? Health Policy 119(2), 212–216 (2015)CrossRefPubMed

30.

PR Newswire. Celltrion signs manufacturing agreement with Bristol-Myers Squibb Company. http://www.prnewswire.co.uk/news-releases/celltrion-signs-manufacturing-agreement-with-bristol-myers-squibb-company-153811165.html (2014). Accessed 9 Dec 2014

31.

Reuters. S.Korea’s Celltrion shares jump on reports of bid interests from Roche, Teva. http://www.reuters.com/article/2014/01/08/celltrion-sale-idUSL3N0KI0MD20140108 (2014). Accessed 9 Dec 2014

32.

Brinks, V., Hawe, A., Basmeleh, A.H., et al.: Quality of original and biosimilar epoetin products. Pharm. Res. 28(2), 386–393 (2011)PubMedCentralCrossRefPubMed

33.

DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug development costs. J Health Econ 22(2), 151–185 (2003)CrossRefPubMed

34.

Curto, S., Ghislandi, S., van de Vooren, K., Duranti, S., Garattini, L.: Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy 116(2–3), 182–187 (2014)CrossRefPubMed

Titel: Western European markets for biosimilar and generic drugs: worth differentiating
verfasst von: Livio Garattini
Alessandro Curto
Katelijne van de Vooren
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 7/2015
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-015-0684-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Using price–volume agreements to manage pharmaceutical leakage and off-label promotion

Health system characteristics and unmet care needs in Europe: an analysis based on EU-SILC data

Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries

Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data

Healthy donor effect and satisfaction with health

Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data